HC Terbinafine

Quick links

Choose a section

Quick links to important sections

Advertisements

HC Terbinafine

Advertisements
Advertisements

Method of action: Antifungal Broad Spectrum

Advertisements

Overview of HC Terbinafine

Quick Facts: Terbinafine Hydrochloride

Property Description
Active Ingredient Terbinafine
Form Tablets (Prescription-only), Creams, Gels, Solutions (OTC/Rx)
Pharmacological Class Allylamine Antifungal
General Purpose Treatment of Fungal Infections (e.g., Athlete's Foot, Nail Infections)
Origin Synthetic Compound

What Type of Medicine is Terbinafine Hydrochloride?

Terbinafine Hydrochloride (HC Terbinafine) is a synthetic pharmaceutical drug that acts as a potent antifungal agent. It is the hydrochloride salt form of the active substance, Terbinafine, and belongs to the distinctive allylamine class of antimycotic compounds. Oral formulations of Terbinafine are clinically recognized as a first-line systemic treatment for fungal nail infections, highlighting the drug's high efficacy against dermatophytes, which are the most common cause of these conditions. This classification confirms the medicine's role in specifically targeting and managing infections caused by pathogenic fungi.


Composition and Available Forms of HC Terbinafine

The medication is primarily manufactured as a single-active-ingredient product (monotherapy), containing only Terbinafine as the therapeutic agent. The drug is available in both systemic and local dosage forms. For infections requiring internal action, it is prepared as oral tablets. For superficial skin infections, it is available in topical preparations, including creams, gels, solutions, or sprays. Terbinafine is an allylamine antifungal and is active against the common strains of fungi that cause ringworm, jock itch, and athlete's foot. This diversity in formulation allows healthcare providers to choose the most appropriate administration route based on the infection's location and severity.


The General Purpose and Action of this Antifungal Agent

The general purpose of this medication is to eradicate fungal infections through a powerful fungicidal action. This means the drug is designed to kill the fungal cells directly. This effect is achieved by specifically blocking the enzyme squalene epoxidase, a critical step in the fungal cells' membrane synthesis pathway. By disrupting this pathway, the medication causes toxic components to accumulate inside the cell, ultimately leading to fungal cell death. This direct and targeted disruption of the fungal lifecycle is the foundation for the medicine's strong therapeutic benefit.

Advertisements

What side effects are possible with HC Terbinafine?

Possible side effects and safety information

The official safety profile of oral HC Terbinafine organizes possible adverse reactions according to frequency and the body system affected, as classified in regulatory documents.


Adverse Reaction Classifications

Side effects are categorized by incidence, ranging from Very Common to Very Rare.

System Organ Class (SOC) Examples of Documented Reactions
Gastrointestinal disorders Nausea, diarrhea, dyspepsia, mild abdominal pain (Very Common)
Nervous system disorders Headache (Very Common), taste disturbance (Common), dizziness (Common)
Skin and subcutaneous tissue disorders Rash, urticaria (Very Common)
Hepatobiliary disorders Hepatitis, jaundice, increased hepatic enzymes (Rare)
Blood and lymphatic system Neutropenia, agranulocytosis (Very Rare)

Serious Adverse Reactions and Safety Constraints

Official labeling documents specific, rare, but clinically significant risks. Hepatic failure, which may be fatal or require a liver transplant, and severe skin reactions (such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis) are documented as Very Rare adverse reactions.

Regulatory safety constraints apply to specific populations. The medicine is contraindicated for individuals with chronic or active hepatic disease. It is also not recommended for use in patients with severe renal impairment (Creatinine Clearance less than 50 mL/min). Post-marketing surveillance indicates that taste and smell disturbances may, in isolated cases, be prolonged or permanent, and a majority of hepatic reactions occur within the first two months of treatment.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Regulatory information describes the official overdose profile for HC Terbinafine (oral form) based on reported acute exposure, including doses up to 5 grams (g) of the active substance.


Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Overdose has been associated with headache, nausea, vomiting, epigastric pain, and dizziness
Physiological systems affected (as stated in label) Gastrointestinal and Central Nervous System symptoms are the documented manifestations following acute overdose
Dose-related or exposure-related factors (if applicable) The maximum acute overdose reported in regulatory documents is up to 5 grams (g) of the active substance
Emergency-response statements (as written in official documents) The recommended treatment is elimination of the active substance, primarily by the administration of activated charcoal and symptomatic supportive therapy
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for overdose, even if symptoms are absent; hospital monitoring is required. Call emergency services at 911 if the individual has collapsed, seized, has trouble breathing, or cannot be awakened

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity classification (as defined in official documents) The reported overdose manifestations are primarily classified as Gastrointestinal and Central Nervous System symptoms
Overdose-context constraints (as defined in official documents) No specific antidote is documented

Resulting Overdose Structure

Official overdose statements:

  • Overdose is documented to present with gastrointestinal symptoms, including nausea, vomiting, and epigastric pain, alongside central nervous system effects such as headache and dizziness.
  • Acute management involves elimination of the drug, principally through the administration of activated charcoal, followed by symptomatic supportive therapy.
  • Immediate response mandates seeking medical attention and hospital monitoring for any overdose event.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile of HC Terbinafine based on reported clinical manifestations, focusing on the occurrence of gastrointestinal and CNS symptoms. This profile mandates immediate, non-negotiable emergency actions, including seeking medical attention and contacting poison control, irrespective of the presence of severe systemic effects. Official labeling outlines specific procedural steps for clinical management, primarily centered on drug elimination and supportive care.

Advertisements

Therapeutic Uses of HC Terbinafine

What HC Terbinafine Treats: Main Uses and Benefits

HC Terbinafine provides specific therapeutic support against pathogenic fungi, primarily targeting the conditions they cause and the resultant symptomatic distress. The medication is used to address infections of the skin, nails, and scalp caused by susceptible fungi, focusing on clinical management.

The medication is commonly used for managing dermatophyte infections such as Onychomycosis (fungus of the nail plate), Tinea Capitis (scalp ringworm), Tinea Corporis (body ringworm), and Tinea Pedis (athlete's foot).


Clearing Deep-Seated Fungal Disease in Nails and Hair

This medication is commonly used for managing deep-seated dermatophyte infections, such as those that involve the nail matrix or hair follicle where topical approaches may not be appropriate. It plays a role in managing the fungal organism in the deep tissue, which supports the outgrowth of healthy tissue and contributes to managing structural integrity. The use of this antifungal supports efforts to ease the impact of chronic disfigurement linked to nail and scalp infections.

Managing Extensive or Refractory Skin Fungal Manifestations

HC Terbinafine is applied in settings of widespread skin infections, or where localized symptomatic support has been insufficient. The benefit is that it supports the management of the fungal organism, which may assist with easing pronounced symptoms of intense itching and burning, thereby contributing to easing the overall symptom burden and supports daily comfort.


Quick Fact: Relief for Dermatological Discomfort
Symptom Axis: Symptoms related to inflammatory or irritative states.
Commonly Used For: Conditions presenting with localized discomfort, such as scaly, peeling lesions and pruritus (itching).
Benefit Focus: Assists with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview on Terbinafine
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

Oral HC Terbinafine eligibility is determined by specific exclusions and restrictions documented in official regulatory labeling (e.g., FDA, EMA). Use is generally established for adults for approved systemic fungal infections.


Absolute Non-Eligibility (Contraindications)

  • Chronic or Active Liver Disease: The medicine is contraindicated and must not be used in patients with pre-existing chronic or active hepatic (liver) disease.
  • Hypersensitivity: Individuals with a history of allergic reaction or hypersensitivity to oral terbinafine or any component of the formulation are strictly contraindicated.
  • Lactation/Breastfeeding: Use is not recommended or contraindicated as the substance is excreted into breast milk.

Restricted and Conditional Use

Population/Condition Regulatory Eligibility Status
Renal Impairment Not recommended if creatinine clearance is le 50 mL/min (use has not been adequately studied).
Children Safety and efficacy are not established for children under 4 years of age. Use in older children is condition- and weight-dependent.
Pregnancy Not recommended unless potential benefit justifies the risk, as clinical experience is very limited.
Lupus/Psoriasis Use requires caution, as precipitation or exacerbation of these conditions has been reported post-marketing.
Advertisements

What should I know about interactions with other medicines?

Drug Interactions

HC Terbinafine is a known inhibitor of the CYP450 2D6 (CYP2D6) enzyme, which is responsible for metabolizing many prescription medicines. This inhibition is the primary cause of potential drug interactions and can significantly increase the concentration of co-administered drugs that are substrates of CYP2D6, potentially converting extensive metabolizers to poor metabolizer status.

Interacting Product Category Example Medicines Interaction Outcome
CYP2D6 Substrates Antidepressants, Beta-blockers (e.g., Metoprolol), Antiarrhythmics, Tamoxifen Clearance of co-administered drug is reduced, leading to increased plasma concentrations and potential toxicity.
CYP450 Inhibitors Cimetidine, Fluconazole May decrease Terbinafine clearance, leading to increased Terbinafine plasma concentrations.
CYP450 Inducers Rifampin May increase Terbinafine clearance, leading to decreased Terbinafine plasma concentrations.

Use of oral Terbinafine is contraindicated with certain CYP2D6-metabolized medicines, such as Pimozide and Thioridazine, due to the potential for serious adverse events. Caution and dose adjustment are generally required when Terbinafine is co-administered with other sensitive CYP2D6 substrates (e.g., Desipramine, Caffeine), to manage the risk of increased exposure and side effects.

Advertisements

Mechanism of Action

The mechanism of action for this combination product involves two distinct and complementary physiological domains.

Targeting Fungal Cell Membrane Synthesis

The antifungal component acts as a non-competitive inhibitor of the enzyme Squalene Epoxidase ( SE) within the fungal cell. Blocking this enzyme prevents the formation of ergosterol, an essential component of the fungal cell membrane, while causing the toxic buildup of its substrate, squalene. This cascade leads to the structural failure of the fungal organism, resulting in cell lysis due to membrane instability and internal toxicity.

Glucocorticoid Receptor-Mediated Anti-inflammatory Modulation

The corticosteroid component activates intracellular Glucocorticoid Receptors ( GR) in the host's skin cells, initiating gene modulation that suppresses the inflammatory response. This action increases the production of proteins that inhibit the Arachidonic Acid Cascade, thereby halting the synthesis of inflammatory mediators like prostaglandins and leukotrienes. This mechanism contributes to the modulation of immune signaling and reduction of local vascular permeability.

Mechanistic Synergism of Dual-Targeting Action

These components provide complementary physiological actions that target two separate mechanistic processes: the pathogen's viability and the host's localized immune response. This synergy results in the concurrent modulation of both the pathogen's viability and the host's inflammatory response pathways.

Advertisements

Dosage and Administration Information

How to Use HC Terbinafine

Terbinafine Hydrochloride is administered via oral or topical routes, with the choice of route dependent on the type and location of the fungal infection. The oral route is employed for systemic treatment of infections like onychomycosis, utilizing a 250 mg tablet strength. Topical applications, such as 1% creams, gels, or solutions, are designated for localized surface infections.


Standard Dosing and Administration Context

The standard adult oral dosage is 250 mg taken once daily. The tablets may be taken either with or without food; however, maintaining a consistent time of day for administration is advised. For children with Tinea Capitis, oral dosing is determined by body weight, ranging from 125 mg to 250 mg once daily. Oral granules, when prescribed, must be mixed with a spoonful of soft, non-acidic food and swallowed immediately, specifically avoiding fruit-based mixers.


Treatment Duration and Specific Constraints

The duration of oral treatment is fixed according to the site of infection. For fingernail onychomycosis, the labeled duration is typically 6 weeks, while toenail onychomycosis requires 12 weeks of daily use. Treatment courses for skin infections such as Tinea Corporis usually range from 2 to 6 weeks. The use of the oral formulation is officially not recommended in patients with pre-existing chronic or active liver disease or significant renal impairment (creatinine clearance le 50 mL/min).

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for HC Terbinafine

Studies conducted on Terbinafine Hydrochloride research examined the medicine's profile based on the fungal infection being studied and the product type (oral tablet or topical form). Studies are designed to explore the measurement of changes in the presence of the fungus itself (mycological outcomes) and the measurement of changes in the visible signs of the infection (clinical outcomes).

Evidence for Use in Fungal Nail Infections (Onychomycosis)

This section will summarize the structure of the high-level evidence, primarily based on randomized controlled trials (RCTs) and systematic reviews, that examined the clinical outcomes of oral tablet use for fungal infection of the nail plate.

Studies examining the oral tablets are predominantly relevant in research exploring fungal infections of the toenails and fingernails. Researchers have applied these studies to examine how the medicine was observed in adult populations and in certain subgroups, such as older adults. The outcomes related to physical discomfort that were most commonly measured included Mycological Cure (laboratory test results indicating the absence of fungus) and Clinical Cure (visual change in the nail’s appearance).

However, certain aspects remain uncertain. Long-term outcomes are not fully established, as follow-up durations were limited in some research, often extending only up to a couple of years after the treatment ended. Research examining how the medicine was observed in studies comparing it to all other alternatives remains an area where more studies could contribute to the broader evidence landscape.

Evidence for Use in Superficial Skin Fungal Infections

This section will detail the research foundation, drawn largely from placebo-controlled trials and meta-analyses, that studied topical preparations (creams, gels) for localized dermatophyte conditions, including Tinea Pedis, Tinea Corporis, and Tinea Cruris.

Research exploring the topical forms is based on numerous Placebo-Controlled Trials used in research exploring how symptoms change over time. Studies monitored key endpoints, including outcomes linked to inflammatory or irritative states, such as the measurement of changes in visible lesions and scaling. Findings describe patterns observed related to patient-reported outcomes describing perceived discomfort, such as itching and burning.

Evidence in Specific Patient Populations

Specific research has been applied in studies examining patient-reported experiences in certain populations. For instance, the medicine was evaluated in studies involving older adults (ages 65 and above), with research examining outcomes related to systemic or functional imbalance. Data for certain groups, particularly very young children or pregnant populations, remain insufficient in large-scale, dedicated RCTs.

Key Studies & References

  1. Antifungal Agents - StatPearls Publishing (General Antifungal Class and Clinical Use)
  2. DailyMed - TERBINAFINE HYDROCHLORIDE tablet (Official Label/Regulatory Information)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about HC Terbinafine (FAQ)


Q: How quickly does HC Terbinafine start working for fungal infections?

A: Studies and official information indicate that visible results for fungal infections, especially those affecting the nails, are not immediate. The clinical effect for nail infections is typically observed some months after treatment is stopped, which is related to the time needed for the healthy nail to grow out. For skin infections, the full clearing of signs and symptoms may also take several weeks after the fungus is no longer detected.


Q: How long do most people take HC Terbinafine for?

A: Regulatory documents outline the standard oral duration based on the infection site. The standard course is 6 weeks for most fingernail fungal infections and 12 weeks for most toenail fungal infections. Treatment periods for superficial skin infections typically range from 2 to 6 weeks of use.


Q: What is the difference between HC Terbinafine and an antifungal cream?

A: HC Terbinafine is the active ingredient in both forms. It is available as an oral tablet for systemic treatment that works internally against conditions like nail infections, and in various topical forms (creams, solutions). Official product information notes that the choice of form is based on the type and location of the infection.


Q: What are the most common side effects people report when taking HC Terbinafine?

A: According to official product information, the most common side effects reported are often mild. These include headache, rash, nausea, diarrhea, stomach upset (dyspepsia), and changes in taste.


Q: Is HC Terbinafine available as a topical treatment as well?

A: Yes, in addition to the oral tablet, HC Terbinafine is available as topical preparations, such as creams, gels, and solutions. These forms are intended for treating localized fungal infections on the surface of the skin.


Q: Why is it important to complete the full course of HC Terbinafine?

A: Fungal infections are known to be slow to clear. Regulatory guidance advises that treatment needs to be completed for the full time prescribed. Stopping treatment prematurely is associated with the possibility of the infection recurring.


Q: Is HC Terbinafine the same as generic terbinafine?

A: HC Terbinafine refers to terbinafine hydrochloride, which is the chemical name for the active antifungal substance. The medicine may be sold as the generic drug 'terbinafine' or under various different brand names.


Q: What should I do if my symptoms improve early while taking HC Terbinafine?

A: Official information emphasizes the importance of using the medication for the full prescribed duration, even if symptoms appear to clear up earlier. This is key for ensuring the infection is completely cleared.


Q: Is HC Terbinafine safe to use for children?

A: The safety and effectiveness of the oral form of HC Terbinafine have not been established for children under 4 years of age. For children older than 4, use is condition-dependent and is often determined based on body weight, as outlined in official documents.


Q: Does HC Terbinafine affect the liver?

A: Yes, oral HC Terbinafine can affect the liver. Official labeling states that the medicine is contraindicated for patients with pre-existing chronic or active liver disease. Rare cases of serious liver problems, including liver failure, have been reported in post-marketing data.


Q: What is the risk of skin rash with HC Terbinafine?

A: Skin rash is a possibility, listed as a Very Common adverse reaction in regulatory documents. Additionally, more severe skin reactions, such as Stevens-Johnson Syndrome, are rare but documented, requiring vigilance.


Q: Is there any research on long-term effects of taking HC Terbinafine?

A: Official documents note that follow-up periods in some clinical studies were limited, meaning certain aspects of the long-term outcomes are not fully established. Information on prolonged use is best reviewed with a healthcare provider.


Q: Can pregnant or breastfeeding women use HC Terbinafine?

A: Oral HC Terbinafine is not recommended during pregnancy due to limited clinical experience, unless potential benefit is judged to justify the risks. It is also not recommended for women who are breastfeeding, as the active substance passes into breast milk.


Q: What happens if I forget to take a dose of HC Terbinafine?

A: Official patient information outlines specific steps for a missed dose, generally advising to skip the missed dose and not take extra medicine if the next dose is near. You should refer to the full patient instructions for guidance on missed doses.


Q: Why do some people experience changes in taste while taking HC Terbinafine?

A: Taste disturbance is a documented side effect, though the exact reason is not fully known. Some data suggests it may be related to the drug's effects on taste receptors or nerves. In rare instances, official reporting indicates this change can be prolonged or permanent.


Q: Can HC Terbinafine make me sensitive to the sun?

A: Regulatory patient resources note that oral HC Terbinafine may make the skin more sensitive to sunlight, and planning to limit unnecessary exposure is usually advised. This includes avoiding artificial light sources like tanning beds.


Q: Is there a maximum time limit for using HC Terbinafine?

A: Official labeling establishes specific, fixed durations for treatment, such as 12 weeks for toenail infections. These fixed periods are generally the recommended maximum for achieving therapeutic success, and any need for extended use requires a re-evaluation.


Q: What is the evidence behind HC Terbinafine's use for nail fungus?

A: The evidence supporting the use of oral tablets for fungal nail infections (onychomycosis) is primarily drawn from Randomized Controlled Trials (RCTs). These studies measured the effectiveness based on outcomes like Mycological Cure (laboratory confirmation of fungus absence) and Clinical Cure (visual improvement).


Q: What are the signs of a serious side effect from HC Terbinafine that people should be aware of?

A: Official labeling documents warn about serious adverse reactions, including signs of liver problems (e.g., persistent nausea, dark urine, or yellowing of the skin/eyes) and severe skin reactions (e.g., blistering or peeling). Should these signs occur, immediate professional medical attention is warranted.


Q: Are there any known interactions between HC Terbinafine and alcohol?

A: While regulatory labeling may not list alcohol as a direct drug interaction, caution is needed. Because oral HC Terbinafine is associated with a risk of liver problems, consuming alcohol could potentially worsen this underlying risk of hepatotoxicity.


Q: What is the half-life of HC Terbinafine in the body?

A: Official pharmacokinetics data states the effective half-life of HC Terbinafine in the bloodstream is about 36 hours. However, due to slow elimination from certain tissues, the terminal half-life can be much longer, ranging between 200 to 400 hours.


Q: Can HC Terbinafine cause stomach upset or diarrhea?

A: Yes. Gastrointestinal issues are listed in official documents as a Very Common side effect. These problems include nausea, diarrhea, stomach upset (dyspepsia), and mild abdominal pain.


Q: What should be discussed with a healthcare provider before starting HC Terbinafine?

A: Patient counseling information advises discussing the patient’s full medical history, all other medicines, supplements, and herbal products being used, and the potential for rare serious effects. This is standard guidance before beginning any new medication.


Q: Is HC Terbinafine used for yeast infections?

A: HC Terbinafine is primarily indicated for infections caused by dermatophyte fungi (such as athlete's foot and nail infections). While scientific data shows some laboratory activity against certain types of yeast, like Candida albicans, its official purpose is centered on dermatophyte infections.


Q: Can HC Terbinafine be taken with supplements or vitamins?

A: Official patient resources recommend informing a healthcare provider about all vitamins, nutritional supplements, and herbal products being taken. This allows the provider to assess potential interactions and determine if any monitoring is required.


Q: Are there any specific lifestyle changes recommended while taking HC Terbinafine?

A: Official resources suggest general hygiene practices for skin infections, such as carefully drying affected areas after bathing, and the use of clean cotton socks and well-ventilated shoes. These measures are intended to support the treatment of localized conditions.


Q: What are the common misunderstandings about how long it takes to see results with HC Terbinafine?

A: A common misunderstanding relates to the timeline for nail infections. Official information indicates that because the infected nail must grow out fully, the most significant positive clinical effect is seen months after the full course of treatment is finished, rather than immediately when the fungus is killed.

Advertisements

How should HC Terbinafine be stored and disposed of?

Official Storage and Disposal Requirements

The storage of terbinafine hydrochloride (HC Terbinafine) must comply with specific regulatory standards to ensure product integrity.

  • Temperature: Both the oral tablets and topical cream must be stored at Controlled Room Temperature, defined as 20 to 25 C (68 to 77 F).
  • Protection: Tablets must be kept in a tight container and protected from light. Topical cream is typically directed to be stored in the original package.
  • Child Safety: All forms of the medicine must be stored out of the sight and reach of children.
  • Disposal: Unused or expired product must be disposed of in accordance with local requirements for medicinal waste. Certain tablet formulations may have no special requirements for disposal, but local protocols must always be followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of HC Terbinafine found in:

A-Z Index: